Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…Abstract Number: 546 • 2017 ACR/ARHP Annual Meeting
Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) have been widely used in patients who failed conventional DMARDs in the treatment of rheumatoid arthritis (RA). While most…Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…Abstract Number: 606 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.1, 2…Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…Abstract Number: 630 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial
Background/Purpose: To evaluate physical and mental health functioning, health state, and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA) treated with…Abstract Number: 1570 • 2017 ACR/ARHP Annual Meeting
Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease characterized by new bone growth that leads to syndesmophyte formation and subsequent vertebral ankyloses, although AS…Abstract Number: 638 • 2017 ACR/ARHP Annual Meeting
Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?
Background/Purpose: Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with psoriatic arthritis (PA) in clinical remission. To evaluate if there are clinical, demographic…Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting
Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment
Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…Abstract Number: 1049 • 2017 ACR/ARHP Annual Meeting
Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis
Background/Purpose: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown to predict 52-week anti-TNF therapeutic outcomes in rheumatoid arthritis (RA).1 HRV…Abstract Number: 2449 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis
Background/Purpose: Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 29
- Next Page »